Equities analysts expect that Applied Genetic Technologies Corporation (NASDAQ:AGTC) will post $0.11 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Applied Genetic Technologies Corporation’s earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at $0.65. Applied Genetic Technologies Corporation posted earnings per share of $0.15 in the same quarter last year, which suggests a negative year over year growth rate of 26.7%. The company is expected to issue its next quarterly earnings results on Monday, September 11th.

According to Zacks, analysts expect that Applied Genetic Technologies Corporation will report full-year earnings of $0.32 per share for the current fiscal year, with EPS estimates ranging from $0.06 to $0.89. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.22) per share, with EPS estimates ranging from ($1.11) to $0.52. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by $0.04. The company had revenue of $8.39 million for the quarter, compared to analysts’ expectations of $10.39 million. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. The firm’s quarterly revenue was down 30.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.11 EPS.

Several research firms have commented on AGTC. Zacks Investment Research cut shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Stifel Nicolaus lowered their target price on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 11th. Cantor Fitzgerald set a $15.00 target price on shares of Applied Genetic Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, May 10th. HC Wainwright set a $16.00 target price on shares of Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research note on Saturday, June 10th. Finally, ValuEngine cut shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Applied Genetic Technologies Corporation presently has a consensus rating of “Buy” and a consensus price target of $13.81.

ILLEGAL ACTIVITY WARNING: “Analysts Expect Applied Genetic Technologies Corporation (NASDAQ:AGTC) to Post $0.11 Earnings Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/10/analysts-expect-applied-genetic-technologies-corporation-nasdaqagtc-to-post-0-11-earnings-per-share.html.

Several institutional investors have recently made changes to their positions in AGTC. Trexquant Investment LP boosted its position in shares of Applied Genetic Technologies Corporation by 3.2% in the second quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 611 shares in the last quarter. CAPROCK Group Inc. boosted its position in shares of Applied Genetic Technologies Corporation by 55.8% in the first quarter. CAPROCK Group Inc. now owns 17,215 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 6,165 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Applied Genetic Technologies Corporation during the first quarter valued at about $123,000. Wells Fargo & Company MN boosted its position in shares of Applied Genetic Technologies Corporation by 1.1% in the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 200 shares in the last quarter. Finally, Smith Asset Management Group LP acquired a new position in shares of Applied Genetic Technologies Corporation during the first quarter valued at about $141,000. 62.22% of the stock is currently owned by institutional investors.

Applied Genetic Technologies Corporation (NASDAQ AGTC) traded up 1.00% during mid-day trading on Thursday, reaching $5.05. 146,484 shares of the company were exchanged. The stock has a market capitalization of $91.28 million, a P/E ratio of 12.05 and a beta of 1.68. The company’s 50 day moving average price is $4.99 and its 200-day moving average price is $6.10. Applied Genetic Technologies Corporation has a 12 month low of $4.50 and a 12 month high of $15.78.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Get a free copy of the Zacks research report on Applied Genetic Technologies Corporation (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.